RxDoctor Payments Data

Brian Shayota

Pediatrics · Salt Lake City, UTNPI 1861806523

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $57,261 of the $92,911 with a category attached, or 61.6%. 11 manufacturers reported payments, led by Chiesi USA, Inc. at 35.1% of the total. 2025 is the largest year on record at $58,948, more than ten times the $156 reported in 2019. Among pediatrics clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$92,911in general payments, 2019–2025

Across 122 payments — averaging $761.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$33K
  • Sanofi$28K
  • Amgen$16K
  • Amicus Therapeutics, Inc.$8K
  • Travere Therapeutics, Inc.$4K
  • Modernatx, Inc.$3K
  • plus $683 from 5 others
$293,262in research payments, 2019–2025

Across 37 payments — averaging $7926.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ultragenyx Pharmaceutical Inc.$142K
  • Modernatx, Inc.$121K
  • Takeda Pharmaceuticals U.S.A., Inc.$30K

What the payments were for

  • Consulting fees$15,82117%
  • Speaking & faculty fees$57,26162%
  • Travel & lodging$16,23617%
  • Food & beverage$3,4434%
  • Education$1500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,911 in reported general payments places this provider in the 95th percentile of 439 pediatrics providers in Utah.

See all pediatrics providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
CerdelgaEliglustat Tartrate12$377,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiCerdelga$28,353$377,68512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 439 pediatrics providers in Utah.

Other pediatrics in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →